Rovaleucel

诺瓦仑赛

Report date: 2022/12/17 17:10:15

Base Information

Drug NameRovaleucel
Drug Alias NameEBV specific cytotoxic T lymphocytes (Tessa Therapeutics)Epstein-Barr virus specific autologous cytotoxic T-lymphocytes therapy (Tessa Therapeutics)Autologous EBV specific Cytotoxic T Lymphocytes (Tessa Therapeutics)Epstein-Barr Virus-Specific T Cells (EBVSTs)EB-VST (Tessa Therapeutics) +[8] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Cytotoxic T-lymphocytes therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsNasopharyngeal Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesTessa Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTessa Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsNasopharyngeal Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A